EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Ibrahima Diouf, Charles B Malpas, Sifat Sharmin, Izanne Roos iD, Dana Horakova, Eva Kubala Havrdova, Francesco Patti iD, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj and 48 more

European Journal of Neurology · 2023

DOI: 10.1111/ene.15706 ↗

At a glance

Journal article in European Journal of Neurology, 2023. Written by Ibrahima Diouf and 59 co-authors. Institution: Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia. Major MEDLINE topics: Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting. Cited 8 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council, Roche.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and purpose This study assessed the effect of patient characteristics on the response to disease‐modifying therapy (DMT) in multiple sclerosis (MS).

Methods

We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow‐up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12‐month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics.

Results

Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio [HR] = 0.52, 95% confidence interval [CI] = 0.45–0.60), 46% lower risk of disability worsening (HR = 0.54, 95% CI = 0.41–0.71), and 32% greater chance of disability improvement (HR = 1.32, 95% CI = 1.09–1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral magnetic resonance imaging activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity.

Conclusions

DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence of attenuation of the effect of DMT with age.

Subjects

MeSH terms (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingHumansImmunotherapyProportional Hazards ModelsRecurrence

Author keywords

EDSSimmunotherapymarginal structural modelmultiple sclerosisrelapse

Authors and institutions

  • Department of Medicine, CORe, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Neurology, Neuroimmunology Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
  • Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy.
  • Isfahan University of Medical Sciences, Isfahan, Iran.
  • Dokuz Eylul University, Konak/Izmir, Turkey.

ORCID profiles: Izanne Roos, Francesco Patti, Murat Terzi, Diana Ferraro, Bassem Yamout, Vincent van Pesch, Yolanda Blanco

Funding

  • National Health and Medical Research Council
  • Roche

Cite

APA

Diouf, I., Malpas, C. B., Sharmin, S., Roos, I., Horakova, D., Havrdova, E. K., Patti, F., Shaygannejad, V., Ozakbas, S., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Alroughani, R., Prat, A., Girard, M., Duquette, P., Terzi, M., Boz, C., …, & Prevost, J. (2023). Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.15706

Vancouver

Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Havrdova EK, et al. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. 2023. doi:10.1111/ene.15706

BibTeX
@article{Diouf2023,
  author = {Diouf, Ibrahima and Malpas, Charles B and Sharmin, Sifat and Roos, Izanne and Horakova, Dana and Havrdova, Eva Kubala and Patti, Francesco and Shaygannejad, Vahid and Ozakbas, Serkan and Izquierdo, Guillermo and Eichau, Sara and Onofrj, Marco and Lugaresi, Alessandra and Alroughani, Raed and Prat, Alexandre and Girard, Marc and Duquette, Pierre and Terzi, Murat and Boz, Cavit and Grand'Maison, Francois and Hamdy, Sherif and Sola, Patrizia and Ferraro, Diana and Grammond, Pierre and Turkoglu, Recai and Buzzard, Katherine and Skibina, Olga and Yamout, Bassem and Altintas, Ayse and Gerlach, Oliver and van Pesch, Vincent and Blanco, Yolanda and Maimone, Davide and Lechner-Scott, Jeannette and Bergamaschi, Roberto and Karabudak, Rana and Iuliano, Gerardo and McGuigan, Chris and Cartechini, Elisabetta and Barnett, Michael and Hughes, Stella and Sa, Maria José and Solaro, Claudio and Kappos, Ludwig and Ramo-Tello, Cristina and Cristiano, Edgardo and Hodgkinson, Suzanne and Spitaleri, Daniele and Soysal, Aysun and Petersen, Thor and Slee, Mark and Butler, Ernest and Granella, Franco and de Gans, Koen and McCombe, Pamela and Ampapa, Radek and Van Wijmeersch, Bart and van der Walt, Anneke and Butzkueven, Helmut and Prevost, Julie},
  title = {Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15706}
}
Start for free →